MA, MBBCh, MRCGP, FRACGP, DPhil, Director Primary Care Collaborative Cancer Clinical Trials Group (PC4), Herman Professor of Primary Care Cancer Research, Department of General Practice, and Centre for Cancer Research, University of Melbourne, Vic
Prescribing drugs to reduce the risk of cancer is a new development in primary cancer prevention.
Expected frequency trees can be used to promote appropriate patient choice of colorectal cancer screening modality.
It is essential to involve primary healthcare professionals as stakeholders in the development of research questions and study design to ensure relevance and feasibility.
In addition to a role in cancer surveillance, GPs have key roles in the management of comorbid illness, secondary prevention, health promotion, self-management promotion and coordination of care.
Advances in genomic epidemiology and sequencing technology will change the way GPs practice medicine in the 21st century.
General practitioners’ ability to promptly recognise potentially serious side effects of treatment, especially those unique to newer therapies, can be crucial to patient safety.
General practitioners are ideally placed to offer individuals and couples carrier screening for autosomal recessive and X-linked conditions.
The genomics era is finally upon general practice, and we need to be prepared to meet the challenges it raises and reap its benefits.
Evidence suggests that GPs and their recommendations consistently improve participation in screening for CRC.